SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2024.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
AURORA, Colo. , April 16, 2025 /PRNewswire/ -- AdvancedPCB is proud to announce the appointment of…
MONTREAL, April 16, 2025 /CNW/ - Professors Eric Déziel and Étienne Yergeau are leading two new…
Innovative platform to streamline crisis response, connect individuals to care, and provide real-time behavioral health…
SEOUL, South Korea, April 16, 2025 /PRNewswire/ -- Mezzion Pharmaceuticals, a global leader in the development…
Nation's Leading Infrared and Red-Light Sauna Franchise to Debut in Almaden in Spring 2026 SAN…
Clario's Advanced AI-Powered Platform Streamlines Clinical Document Processing to Facilitate Faster Drug Development Timelines PHILADELPHIA,…